Agios Pharmaceuticals surges after $55 target implies 67% upside

H.C. Wainwright lifted its price target as Q2 2026 revenue reached $44.75 million, helped by stronger-than-expected mitapivat sales that nearly doubled estimates.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.